Krystal Biotech, Inc.

KRYS · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders10.7%

Institutions102.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2017-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$389.13M	$290.51M	$50.70M	–	–	–	–	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$23.05M	$20.06M	$3.09M	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$161.29M	$65.69M	-$109.73M	-$145.20M	-$68.28M	-$33.00M	-$22.08M	-$4.77M
Operating income as a percentage of revenue.	41.5%	22.6%	-216.4%	–	–	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$204.83M	$89.16M	$10.93M	-$139.97M	-$69.57M	-$32.17M	-$19.09M	-$7.92M
Net income divided by the number of shares outstanding — profit attributable to each share.	$7.08	$3.12	$0.40	$-5.49	$-3.13	$-1.71	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$6.84	$3.00	$0.39	$-5.49	$-3.13	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2017-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$496.30M	$344.87M	$358.33M	$161.90M	$341.25M	$268.27M	$187.51M	$49.59M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.33B	$1.06B	$818.36M	$558.45M	$626.29M	–	$209.02M	$50.11M
Everything the company owes — debt, unpaid bills, and other obligations.	$114.23M	$109.46M	$39.71M	$36.22M	$32.72M	–	$6.11M	$640000
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.22B	$946.38M	$778.64M	$522.23M	$593.58M	–	$202.91M	$49.47M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2017-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$200.87M	$123.42M	-$88.80M	-$100.57M	-$47.94M	-$26.08M	-$18.71M	-$3.89M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$11.95M	$4.24M	$11.80M	$52.98M	$68.34M	$14.84M	$6.40M	$210000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$188.91M	$119.18M	-$100.60M	-$153.55M	-$116.27M	-$40.93M	-$25.11M	-$4.10M

	You	Peer avg
P/E	43.5	104.3
Revenue Growth	+24.1%	+77.5%
ROE	20.1%	16.6%

Krystal Biotech, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison